CardioDx 2013 Revenues Rise Sharply | GenomeWeb

NEW YORK (GenomeWeb) – CardioDx's 2013 revenues increased more than three-fold year over year, the company said in a regulatory document on Monday.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission, the Palo Alto, Calif.-based cardiovascular molecular diagnostics firm reported $8.0 million in revenues for 2013, compared to $2.5 million in 2012. Test volume last year rose to 22,371 tests performed, up from 9,990 in 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.